New Immunotherapy Combination Shows Promise in Advanced Cancers
A novel immunotherapy approach combining an experimental antibody with pembrolizumab, a widely used immunotherapy drug, is showing early signs of promise in treating advanced cancers, according to research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.The research,led by Dr. Emily Patz and Dr. Navin Mamdani,focuses on harnessing the body’s immune system to fight tumors.
How the treatment Works
The experimental antibody, developed by researchers at [Institution name – *research needed to identify the institution*], is designed to target and mark cancer cells for destruction. This is then combined with pembrolizumab, marketed as Keytruda by merck & Co., which works by blocking the PD-1 protein, effectively releasing the brakes on the immune system and allowing it to attack cancer cells. Researchers hoped the two drugs would work synergistically,with the antibody pinpointing the cancer and pembrolizumab empowering the immune system to eliminate it.
Early Trial Results: Stabilization and a Rare Remission
While the results are preliminary, the combination therapy has demonstrated some encouraging effects. Researchers observed tumor stabilization in many patients, meaning the cancer wasn’t growing, but some tumors eventually resumed growth. However, one patient experienced a complete remission – their tumor disappeared entirely and has remained undetectable for two years. Dr. Mamdani stated the patient is currently off treatment.
Dr. Patz explained a challenge in interpreting the results: “Our antibody specifically targets and kills tumor cells, but it may not kill them all.” The strategy is to “train the immune system to take care of everything else by adding the Merck drug.”
A key observation highlighted by Dr. Patz was that apparent tumor growth could sometimes be attributed to inflammation caused by immune cell activity, rather then actual cancer cell proliferation. “What we’re finding on imaging and measuring isn’t always cancer cells,” she noted.
The Need for Larger Studies
The researchers emphasize the need for larger, controlled clinical trials with a control group receiving only standard treatment. Dr. Simon, another researcher involved in the study, stated, “We need to study hundreds of patients” to draw definitive conclusions about the efficacy of this combination therapy.
Key Takeaways
- A combination of a novel antibody and pembrolizumab shows early promise in treating advanced cancers.
- Tumor stabilization was observed in many patients, with one patient achieving complete remission.
- Inflammation caused by immune response can sometimes be mistaken for tumor growth on imaging.
- Larger clinical trials are needed to confirm these findings and determine the therapy’s effectiveness.
This research represents a potentially critically important step forward in cancer immunotherapy. While further investigation is crucial, the initial results suggest that combining targeted antibodies with checkpoint inhibitors like pembrolizumab could offer a new avenue for treating challenging cancers. Future studies will focus on identifying which patients are most likely to benefit from this approach and optimizing the treatment regimen for maximum efficacy.